A Phase 2b Study of Dalfampridine 10mg Extended Release Tablet in Subjects With Chronic Deficits After Ischemic Stroke
Public ClinicalTrials.gov record NCT01605825. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a multi-center, safety and tolerability study in subjects with chronic stable sensorimotor deficits after ischemic stroke. It has been designed as a double-blind, placebo-controlled, 2-period crossover study.
Study identification
- NCT ID
- NCT01605825
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 83 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 85 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 2012 (Type not available)
- Primary completion
- Feb 2013 (Actual)
- Completion
- Mar 2013 (Actual)
- Last update posted
- Jan 22, 2016
2012 – 2013
United States locations
- U.S. sites
- 20
- U.S. states
- 16
- U.S. cities
- 20
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Acorda Site #011 | Birmingham | Alabama | 35294 | — |
| Acorda Site #018 | La Jolla | California | 92103 | — |
| Acorda Site #016 | Newport Beach | California | 92663 | — |
| Acorda Site #006 | Fairfield | Connecticut | 06824 | — |
| Acorda Site #002 | Atlantis | Florida | 33462 | — |
| Acorda Site #015 | Fort Lauderdale | Florida | 33308 | — |
| Acorda Site #003 | Decatur | Georgia | 30033 | — |
| Acorda Site #021 | Lexington | Kentucky | 40513 | — |
| Acorda Site #009 | Boston | Massachusetts | 02118 | — |
| Acorda Site #017 | Saginaw | Michigan | 48604 | — |
| Acorda Site #020 | Great Falls | Montana | 59405 | — |
| Acorda Site #023 | Reno | Nevada | 89502 | — |
| Acorda Site #022 | New Brunswick | New Jersey | 08901 | — |
| Acorda Site #019 | Buffalo | New York | 14220 | — |
| Acorda Site #007 | West Haverstraw | New York | 10993 | — |
| Acorda Site #004 | White Plains | New York | 10605 | — |
| Acorda Site #013 | Charlotte | North Carolina | 28207 | — |
| Acorda Site #001 | Philadelphia | Pennsylvania | 19104 | — |
| Acorda Site #008 | Norfolk | Virginia | 23507 | — |
| Acorda Site #010 | Bellevue | Washington | 98004 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01605825, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 22, 2016 · Synced Oct 25, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT01605825 live on ClinicalTrials.gov.